153 related articles for article (PubMed ID: 23934621)
1. The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects.
Ziauddeen H; Nathan PJ; Dodds C; Maltby K; Miller SR; Waterworth D; Song K; Warren L; Hosking L; Zucchetto M; Bush M; Johnson LV; Sarai B; Mogg K; Bradley BP; Richards DB; Fletcher PC; Bullmore ET
J Clin Pharmacol; 2013 Oct; 53(10):1078-90. PubMed ID: 23934621
[TBL] [Abstract][Full Text] [Related]
2. Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498.
Nathan PJ; Bush MA; Tao WX; Koch A; Davies KM; Maltby K; O'Neill BV; Napolitano A; Skeggs AL; Brooke AC; Richards DB; Williams PM; Bullmore ET
J Clin Pharmacol; 2012 Oct; 52(10):1456-67. PubMed ID: 22162534
[TBL] [Abstract][Full Text] [Related]
3. Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects.
Ziauddeen H; Chamberlain SR; Nathan PJ; Koch A; Maltby K; Bush M; Tao WX; Napolitano A; Skeggs AL; Brooke AC; Cheke L; Clayton NS; Sadaf Farooqi I; O'Rahilly S; Waterworth D; Song K; Hosking L; Richards DB; Fletcher PC; Bullmore ET
Mol Psychiatry; 2013 Dec; 18(12):1287-93. PubMed ID: 23147384
[TBL] [Abstract][Full Text] [Related]
4. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
[TBL] [Abstract][Full Text] [Related]
5. Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist.
Nathan PJ; O'Neill BV; Bush MA; Koch A; Tao WX; Maltby K; Napolitano A; Brooke AC; Skeggs AL; Herman CS; Larkin AL; Ignar DM; Richards DB; Williams PM; Bullmore ET
J Clin Pharmacol; 2012 Apr; 52(4):464-74. PubMed ID: 21610207
[TBL] [Abstract][Full Text] [Related]
6. The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.
Ripley TL; Sanchez-Roige S; Bullmore ET; Mugnaini M; Maltby K; Miller SR; Wille DR; Nathan P; Stephens DN
Psychopharmacology (Berl); 2015 Sep; 232(18):3431-41. PubMed ID: 26141191
[TBL] [Abstract][Full Text] [Related]
7. Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.
Chamberlain SR; Mogg K; Bradley BP; Koch A; Dodds CM; Tao WX; Maltby K; Sarai B; Napolitano A; Richards DB; Bullmore ET; Nathan PJ
Psychopharmacology (Berl); 2012 Dec; 224(4):501-9. PubMed ID: 22752384
[TBL] [Abstract][Full Text] [Related]
8. The Novel μ-Opioid Receptor Antagonist GSK1521498 Decreases Both Alcohol Seeking and Drinking: Evidence from a New Preclinical Model of Alcohol Seeking.
Giuliano C; Goodlett CR; Economidou D; García-Pardo MP; Belin D; Robbins TW; Bullmore ET; Everitt BJ
Neuropsychopharmacology; 2015 Dec; 40(13):2981-92. PubMed ID: 26044906
[TBL] [Abstract][Full Text] [Related]
9. Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist.
Ignar DM; Goetz AS; Noble KN; Carballo LH; Stroup AE; Fisher JC; Boucheron JA; Brainard TA; Larkin AL; Epperly AH; Shearer TW; Sorensen SD; Speake JD; Hommel JD
J Pharmacol Exp Ther; 2011 Oct; 339(1):24-34. PubMed ID: 21712426
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating.
Giuliano C; Robbins TW; Nathan PJ; Bullmore ET; Everitt BJ
Neuropsychopharmacology; 2012 Nov; 37(12):2643-52. PubMed ID: 22805601
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of cocaine and heroin seeking by μ-opioid receptor antagonism.
Giuliano C; Robbins TW; Wille DR; Bullmore ET; Everitt BJ
Psychopharmacology (Berl); 2013 May; 227(1):137-47. PubMed ID: 23299095
[TBL] [Abstract][Full Text] [Related]
12. Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people.
Cambridge VC; Ziauddeen H; Nathan PJ; Subramaniam N; Dodds C; Chamberlain SR; Koch A; Maltby K; Skeggs AL; Napolitano A; Farooqi IS; Bullmore ET; Fletcher PC
Biol Psychiatry; 2013 May; 73(9):887-94. PubMed ID: 23245760
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans.
Rabiner EA; Beaver J; Makwana A; Searle G; Long C; Nathan PJ; Newbould RD; Howard J; Miller SR; Bush MA; Hill S; Reiley R; Passchier J; Gunn RN; Matthews PM; Bullmore ET
Mol Psychiatry; 2011 Aug; 16(8):826-35, 785. PubMed ID: 21502953
[TBL] [Abstract][Full Text] [Related]
14. Subjective response to alcohol among alcohol-dependent individuals: effects of the μ-opioid receptor (OPRM1) gene and alcoholism severity.
Ray LA; Bujarski S; MacKillop J; Courtney KE; Monti PM; Miotto K
Alcohol Clin Exp Res; 2013 Jan; 37 Suppl 1(Suppl 1):E116-24. PubMed ID: 23240711
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.
Lowe SL; Wong CJ; Witcher J; Gonzales CR; Dickinson GL; Bell RL; Rorick-Kehn L; Weller M; Stoltz RR; Royalty J; Tauscher-Wisniewski S
J Clin Pharmacol; 2014 Sep; 54(9):968-78. PubMed ID: 24619932
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the safety, pharmacodynamic, and pharmacokinetic effects following oral coadministration of immediate-release morphine with ethanol in healthy male participants.
Setnik B; Sokolowska M; Johnson F; Oldenhof J; Romach M
Hum Psychopharmacol; 2014 May; 29(3):251-65. PubMed ID: 24911576
[TBL] [Abstract][Full Text] [Related]
17. Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.
Sun H; Yee KL; Gill S; Liu W; Li X; Panebianco D; Mangin E; Morrison D; McCrea J; Wagner JA; Troyer MD
J Psychopharmacol; 2015 Nov; 29(11):1159-69. PubMed ID: 26464455
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.
Berger B; Brooks S; Zuiker R; Richard M; Muehlan C; Dingemanse J
CNS Drugs; 2020 Dec; 34(12):1253-1266. PubMed ID: 33205362
[TBL] [Abstract][Full Text] [Related]
19. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans.
Ray LA; Hutchison KE
Alcohol Clin Exp Res; 2004 Dec; 28(12):1789-95. PubMed ID: 15608594
[TBL] [Abstract][Full Text] [Related]
20. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
